IGHE and Alzheimer disease: Furthermore, the patients with serum levels of IgE ≥200 IU/mL demonstrated a 6.25 times higher SALT75 response rate than those with IgE <200 IU/mL after week 72, and dupilumab responders were more likely to have an AD history and/or high serum levels of IgE compared to non-responders [156].